Should the FDA speed up or slow down approval of new cancer drugs?
CARLOS OSORIO/AP
While increased evidence requirements may improve health outcomes, it's important to consider that the delays they cause may cost lives.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario